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Role of angiotensin II in diabetic nephropathy. Considerable [8–15] of matrix components are responsible for matrix
evidence suggests that the intrarenal renin-angiotensin system accumulation.
plays an important role in diabetic nephropathy. Angioten- Mediators of mesangial matrix expansion in diabeticsin-converting enzyme (ACE) inhibitors and angiotensin II
nephropathy have not been fully identified. A prominent(Ang II) receptor blockers (ARBs) can attenuate progressive
role for the peptide angiotensin II (Ang II) has beenglomerulosclerosis in disease models and can slow disease pro-
gression in humans. Because agents that interfere with Ang II suggested by experimental and clinical evidence indicat-
action may decrease glomerular injury without altering glomer- ing that angiotensin-converting enzyme (ACE) inhibi-
ular pressures, it has been suggested that Ang II has direct
tors and angiotensin receptor blockers (ARBs) have re-effects on glomerular cells to induce sclerosis independent of
noprotective effects that cannot be entirely explained byits hemodynamic actions. To study nonhemodynamic effects
of Ang II on matrix metabolism, many investigators have used their blood pressure lowering effects [16–19]. The ACE
cell culture systems. Glucose and Ang II have been shown to inhibitor enalapril inhibits gene expression of ECM pro-
produce similar effects on renal cells in culture. For instance, teins in diabetic rats [20], suggesting that Ang II is impor-incubation of mesangial cells in high-glucose media or in the
tant in the development of glomerulosclerosis and thatpresence of Ang II stimulates matrix protein synthesis and
preventing its formation can decrease matrix synthesis.inhibits degradative enzyme (e.g., collagenase, plasmin) activ-
ity. Glucose and Ang II also can inhibit proximal tubule pro- However, in studies in whole animals or humans, it is
teinases. Glucose increases expression of the angiotensinogen difficult to separate the effects of blood pressure reduc-
gene in proximal tubule cells and Ang II production in primary
tion from other biochemical effects of these agents.mesangial cell culture, which indicates that high glucose itself
Use of cell culture obviates these problems becausecan activate the renin-angiotensin system. The effects of glu-
cose and Ang II on mesangial matrix metabolism may be medi- it allows separation of hemodynamic and nonhemody-
ated by transforming growth factor-b (TGF-b). Exposure of namic actions of Ang II. Studies using cell culture sys-
mesangial cells to glucose or Ang II increases TGF-b expres- tems have provided data indicating that glucose and Angsion and secretion. Their effects on matrix metabolism can be
II can both directly increase matrix synthesis and de-blocked by anti-TGF-b antibody or ARBs such as losartan,
crease its degradation, and that Ang II inhibitors canwhich also prevents the glucose-induced increment in TGF-b
secretion. Taken together, these findings support the hypothe- decrease glucose-induced matrix accumulation (see sub-
sis that the high-glucose milieu of diabetes increases Ang II sequent discussion).
production by renal, and especially, mesangial cells, which re-
sults in stimulation of TGF-b1 secretion, leading to increased
synthesis and decreased degradation of matrix proteins, thus RENIN-ANGIOTENSIN SYSTEM INproducing matrix accumulation. This may be an important
DIABETIC NEPHROPATHYmechanism linking hyperglycemia and Ang II in the pathogene-
sis of diabetic nephropathy. The status of the renin-angiotensin system (RAS) has
been extensively studied in diabetes. Earlier studies fo-
cused on the systemic RAS, and the data obtained have
Diabetic nephropathy is characterized by expansion been conflicting, with stimulation, suppression, and no
of extracellular matrix (ECM) in the glomeruli, which change in the system being reported [21, 22]. The multi-
eventually leads to proteinuria and renal failure. Accu- tude of factors that influence the systemic RAS in addi-
mulation of ECM components such as collagen has been tion to the different stages of disease and species studied
demonstrated in diabetic glomeruli [1–3] and in mesan- may explain many of these divergent findings. However,
gial cells incubated in high glucose media [4–6]. Both in various diabetic models, increased renal renin content
increased synthesis [4–8] and decreased degradation relative to plasma renin levels has generally been found,
thus suggesting impaired renal renin release into the
Key words: diabetes, angiotensin, glucose, matrix. circulation [22]. Decreased plasma renin activity is fre-
quently observed in clinical diabetic nephropathy, whichÓ 2000 by the International Society of Nephrology
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may be due to nonenzymatic glycation of prorenin with by greater lowering of glomerular capillary pressure with
these agents [31]. However, other mechanisms are proba-decreased conversion to active renin [23]. Thus, diabetic
bly involved in their renoprotective effects. Ang II cannephropathy has traditionally been considered a “low
directly increase cytokine formation and matrix accumu-renin” state. However, plasma renin activity may not
lation and stimulates growth and protooncogenes in re-accurately reflect activity of the RAS in the kidney. An-
nal cells [32]. An increase in proteinuria due to Ang IIother problem has been the difficulty of accurate mea-
may itself lead to accelerated tubulointerstitial injurysurement of plasma Ang II, which is an important issue
[33]. Ang II has recently been demonstrated to increasebecause discordance can exist between plasma renin and
mesangial cell superoxide production and thus may exertAng II levels [24].
oxidant-induced renal injury (discussed later).More recently, the intrarenal RAS has been the focus
of extensive study. Abundant evidence indicates the exis- Effects of glucose and mechanical strain on
tence of local tissue RASs that are regulated indepen- intrarenal RAS
dently of plasma RAS. Ballerman et al. [25] first reported
Cultured glomeruli contain the substrate and enzymesa decrease in glomerular Ang II receptors in the diabetic
needed for Ang II generation [34]. Moreover, recent datarat 3 to 4 weeks after induction of the disease. Downregu-
support the concept that the mesangial cells themselveslation of glomerular Ang II receptors implies that intra-
contain all of the elements of the RAS, including renin,renal Ang II generation may be increased. The density
angiotensinogen, type I angiotensin II (AT1) receptors,of Ang II receptors in the proximal tubules was reported
and ACE [35, 36]. Stretch/relaxation of cultured mesan-
to be reduced in diabetic rats and was accompanied by gial cells has been shown to increase angiotensinogen
decreased mRNA expression for the AT1 receptor [26]. gene expression and production and increase AT1 recep-
Recently, AT1 receptor density has also been shown to tor expression [35]. Thus, not only may Ang II-induced
be down-regulated in mesangial cells incubated in high- hemodynamic changes affect mesangial function but me-
glucose media [27]. Whole kidney ACE activity is low chanical stress per se can increase the activity of the
in diabetes; however, this is probably due primarily to mesangial RAS. Ang II is produced by primary cultures
proximal tubule suppression because staining for ACE of rat mesangial cells and glucose increases Ang II syn-
has been found to be enhanced in glomeruli and vascula- thesis by these cells [37] (Fig. 1). The mechanism by
ture of diabetic rats [28] and in patients with diabetic which glucose increases mesangial Ang II production is
nephropathy [29]. These data suggest that the term “in- currently being studied in our laboratory. A possible
trarenal” RAS is an oversimplification, inasmuch as the mechanism may be stimulation of angiotensinogen gene
vascular RAS (vessels and glomeruli) appears to be regu- expression, as has been demonstrated in tubular cells
lated differently from the tubulointestitial RAS. Renal [38]. The ability of mesangial cells to synthesize Ang II
vasodilation in response to ARBs is enhanced in patients may not require ACE, because angiotensin I formed
with diabetes (despite the presence of low plasma renin from cleavage of angiotensinogen may be converted to
activity), again supporting the concept that the renal Ang II through other peptidases. Thus, in diabetic cell
vascular RAS is activated despite suppression of the culture models, both mechanical and biochemical (i.e.,
circulating RAS (abstract; Price et al, J Am Soc Nephrol high glucose) perturbations can increase the activity of
7:1363, 1996). the intrarenal RAS.
Ang II concentrations in several intrarenal compart-
Effects of glucose and Ang II on matrix metabolismments including the glomeruli have been found to be
several orders of magnitude higher than those found Glucose and Ang II have been shown to have similar
systemically [30]. This supports both the existence of a effects on glomerular cells in culture. For instance, incu-
bation of mesangial cells in high glucose media resultslocal RAS acting independently of the systemic RAS
in stimulation of matrix protein synthesis [4–6, 8]. Angand also is consistent with the finding that in most renal
II has similar effects [39–41]. Both glucose loading [12]cell culture studies, effects of Ang II are observed at sub-
and Ang II [37] inhibit mesangial cell collagenase activ-stantially higher concentrations (about 0.01–1.0 mmol/L)
ity, and these effects are blocked by losartan (Fig. 2).than those found in the systemic circulation.
Glucose-induced collagen accumulation in mesangial
cells is also blocked by losartan [37]. Ang II has been
POTENTIAL MECHANISMS OF demonstrated to increase plasminogen activator inhibi-
ANG II-INDUCED RENAL INJURY tor synthesis and decrease plasminogen activator activity.
Ang II has many physiologic and biochemical effects These alterations in the plasminogen/plasmin system
that could contribute to diabetic nephropathy (Table 1), would lead to decreased matrix degradation and in-
and thus the renoprotective effect of blocking the RAS creased accumulation, both by the direct effects of plas-
undoubtedly results from various mechanisms. The greater min and through plasmin-mediated collagenase activa-
antiproteinuric effects of ACE inhibitors and ARBs com- tion [42, 43]. In proximal tubule cells, glucose and Ang
II also both inhibit proteinase activity [44, 45].pared to other antihypertensive agents may be explained
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Table 1. Proposed mechanisms of angiotensin II effects in diabetic nephropathy
Hemodynamic effects Non-hemodynamic effects
Systemic hypertension Induction of renal hypertrophy and cell proliferation
Systemic and renal vasoconstriction Stimulation of extracellular matrix synthesis
Increased glomerular capillary pressure and permeability Inhibition of extracellular matrix degradation
Mesangial cell contraction leading to reduction in filtration surface area Stimulation of cytokine (e.g., TGF-b, VEGF, endothelin) production
Stimulation of superoxide production
factors [47, 48]. It is therefore likely that TGF-b is in-
volved in the pathogenesis of diabetic nephropathy. In-
deed, the effects of glucose and Ang II on mesangial
matrix metabolism may be mediated by TGF-b. Expo-
sure to high glucose results in an increase in TGF-b
mRNA and secretion in mesangial cells [49, 50]. The
effects of elevated glucose on collagen synthesis can be
blocked by anti-TGF-b1 antibody [51]. Decreased colla-
genase activity in rat mesangial cells after glucose loading
can also be reversed by anti-TGF-b1 antibody, sug-
gesting that this cytokine also affects mesangial matrix
degradative mechanisms (Singh et al, Exp Nephrol, in
press). We have found that exogenous TGF-b1 decreases
matrix metalloproteinase-2 levels and increases tissue
inhibitor of metalloproteinase-2 levels in rat mesangial
cells (Singh et al, Exp Nephrol, in press). Ang II stimu-
lates mesangial matrix synthesis, an effect mediated by
TGF-b [39]. The Ang II competitive inhibitor saralasin
prevented the effects of Ang II [39]. Similar effects of
Ang II on TGF-b synthesis also occur in proximal tubule
cells [52]. In rat mesangial cells, glucose-induced in-
Fig. 1. Angiotensin II production by mesangial cells incubated with creased TGF-b1 secretion is blocked by the Ang II antag-varying concentrations of glucose (5 to 60 mmol/L) for 24 hours. Angio-
onist losartan [37] (Fig. 3). In a study employing AT1atensin II levels were measured in cell extracts by ELISA. Data shown
are the means 6 SEM of four experiments. Glucose loading increased receptor–deficient mice made diabetic with streptozo-
Ang II production in a concentration-dependent manner (*P , 0.05 tocin induction, increased renal TGF-b mRNA levels
vs. 5 mmol/L glucose). (From [37]).
were seen only in mice with an intact renin-angiotensin
system and not in the absence of the AT1a receptor (ab-
stract, Hutchison FN et al, J Am Soc Nephrol, 7:1872–Glucose and Ang II probably use similar signal trans-
1873, 1996), further supporting the hypothesis that theduction pathways in renal cells in culture. Glucose stimu-
increase in TGF-b with diabetes is mediated by Ang II.lates de novo synthesis of diacylglycerol (DAG) gener-
Taken together, these data suggest that the effects ofated from glycolytic intermediates through the polyol
glucose in renal (and especially, mesangial) cells may bepathway; elevated DAG then leads to activation of pro-
mediated by stimulation of Ang II production, whichtein kinase C (PKC), which then increases TGF-b1 syn-
then leads to TGF-b–mediated increased matrix synthe-thesis and matrix protein synthesis in mesangial and tu-
sis and decreased matrix degradation (Fig. 4).bular cells. Ang II activates PKC through the AT1a
receptor. Activation of PKC probably thus occurs both
Ang II-induced vascular growth factor expressionas a direct effect of glucose and by activation of AT1a
Vascular endothelial growth factor (VEGF), also calledreceptors. In addition, additive effects of high glucose
vascular permeability factor (VPF), is a recently de-and Ang II on PKC activation may occur [21].
scribed cytokine believed to be important in the patho-
Effects of glucose and Ang II on TGF-b in genesis of diabetic nephropathy and retinopathy. Most
diabetic nephropathy VEGF expression in the kidney is confined to the glo-
merular epithelial [53] and mesangial [54] cells. Ang IIThe cytokine TGF-b is known to be an important
stimulates the release of VEGF from human vascular tis-mediator of matrix accumulation and fibrosis [46]. Glo-
sues [55] and mesangial cells [56]. Moreover, both Ang IImeruli from diabetic animals and humans have increased
mRNA for TGF-b as well as other growth-promoting and mechanical stretch interact to increase VEGF pro-
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Fig. 3. Total TGF-b1 secretion in media from mesangial cells incubated
in 5 mmol/L glucose (NG), 30 mmol/L glucose (HG), and HG 1 1024 M
losartan (HG 1 L) for 5 days. TGF-b1 was measured by ELISA.
Incubation in high-glucose media produced a significant (P , 0.05)
increase in total TGF-b1 that was blocked by losartan. (From [37]).
ies are needed to examine the effects of VEGF on matrix
accumulation in diabetes [59].
Interaction of the RAS with nitric oxide and
endothelin (ET) in diabetes
Endothelial cells are known to produce vasodilator sub-
stances such as nitric oxide (NO) and vasoconstrictor sub-
stances including endothelin-1 (ET-1). The NO system
appears to be upregulated in diabetic nephropathy [60],
where it serves as a functional antagonist of Ang II. NO
has renal antiproliferative effects and decreases matrix
protein synthesis [61, 62]. NO also inhibits the vasocon-
strictor actions of Ang II on preglomerular arterioles and
down-regulates the synthesis of ACE and AT1 receptors
[63]. Ang II activates nicotinamide adenine dinucleotide
(reduced form)/nicotinamide adenine dinucleotide phos-
Fig. 2. Collagenase activity from mesangial cells incubated in (A) 5
phate (reduced form) oxidase and induces superoxide pro-mmol/L glucose (NG) or 30 mmol/L glucose (HG) in the presence or
absence of losartan (L). Collagenase activity was measured in cell media duction and hypertrophy by mesangial cells. The super-
using fluorescein-labeled gelatin as substrate. Data are the means 6 oxide anion interacts with nitric oxide, thus reducing its
SEM of 9 experiments. The asterisk denotes statistical significance (P ,
bioactivity, and acts as an intracellular signal leading to0.05) compared to NG and HG 1 L. (From [37]). (B) Collagenase
activity from mesangial cells incubated in either 5 mmol/L glucose (NG) cell growth [64]. Ang II is also known to be an important
alone or in the presence of 1026 M Ang II (NG 1 Ang II) or 1026 M stimulus for ET synthesis by endothelial cells and mesan-Ang II plus 1024 M losartan (NG 1 Ang II 1 L). Data shown are the
gial cells [60] and ACE inhibitors and ARBs reduce ET.means 6 SEM of 8 experiments. The asterisk denotes statistical signifi-
cance (P , 0.05) compared to NG and NG 1 Ang II 1 L. (From [37]). The role of these endothelial substances and their rela-
tionship to Ang II in diabetic nephropathy require fur-
ther investigation.
duction by mesangial cells [57]. In one study, glucose
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Fig. 4. Possible mechanisms of glucose-induced
matrix accumulation. DAG, diacylglycerol; PKC,
protein kinase C; Ang II, angiotensin II; TGF-b,
transforming growth factor-beta; PAI-1, plasmin-
ogen activator inhibitor-1; PA, plasminogen activa-
tor; TIMP, tissue inhibitor of metalloproteinase.
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